Get the Stockscreener App
1.44
0.70%
0.01
After Hours:
1.47
0.03
+2.08%
Adicet Bio Inc stock is traded at $1.44, with a volume of 352.02K.
It is up +0.70% in the last 24 hours and down -1.37% over the past month.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its lead product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its lead preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.
See More
Previous Close:
$1.43
Open:
$1.49
24h Volume:
352.02K
Relative Volume:
0.44
Market Cap:
$119.07M
Revenue:
$38.70M
Net Income/Loss:
$-142.66M
P/E Ratio:
-0.5294
EPS:
-2.72
Net Cash Flow:
$-98.18M
1W Performance:
+0.70%
1M Performance:
-1.37%
6M Performance:
-38.72%
1Y Performance:
+5.11%
1-Day Range:
$1.42
$1.51
1-Week Range:
$1.32
$1.51
52-Week Range:
$1.05
$3.77
Adicet Bio Inc Stock (ACET) Company Profile
Name
Adicet Bio Inc
Sector
Industry
Phone
617-482-2333
Address
131 DARTMOUTH STREET, BOSTON
Adicet Bio Inc Stock (ACET) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-27-23 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-27-23 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Jun-01-23 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-21-22 | Initiated | JP Morgan | Overweight |
| Mar-31-22 | Initiated | SMBC Nikko | Outperform |
| Mar-08-22 | Initiated | Truist | Buy |
| Mar-04-22 | Initiated | Jefferies | Buy |
| May-18-21 | Initiated | BTIG Research | Buy |
| Apr-23-21 | Initiated | H.C. Wainwright | Buy |
| Apr-14-21 | Initiated | Canaccord Genuity | Buy |
| Apr-08-21 | Initiated | Guggenheim | Buy |
| Nov-04-20 | Initiated | B. Riley Securities | Buy |
| Oct-27-20 | Initiated | JMP Securities | Mkt Outperform |
| Oct-16-20 | Initiated | Wedbush | Outperform |
View All
Adicet Bio Inc Stock (ACET) Latest News
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - StockTitan
Adicet Bio to Present at the American Society of Gene & Cell Therapy’s (ASGCT) 2024 Advancing Gene + Cell Therapies for Cancer Conference - StockTitan
HC Wainwright Reiterates Neutral Rating for Adicet Bio (NASDAQ:ACET) - MarketBeat
Guggenheim Begins Coverage on Adicet Bio (NASDAQ:ACET) - Defense World
Adicet Opens Enrollment for ADI-001 Phase 1 Clinical Trial in Autoimmune Diseases - BioSpace
Adicet Bio Launches Phase 1 Trial of ADI-001, Eyes Expansion - TipRanks
Adicet Opens Enrollment for ADI-001 Phase 1 Clinical Trial in Autoimmune Diseases - StockTitan
Wall Street SWOT: Adicet Bio stock navigates competitive CAR-T waters - Investing.com
Wall Street SWOT: Adicet Bio stock navigates competitive CAR-T waters - Investing.com India
Biomarker Data from Oncology Trial for Adicet Bio’s Gamma Delta T-cell Therapy ADI-001 Indicates Potential for Use in Autoimmune Disease - CGTLive™
Analysts’ Weekly Ratings Changes for Adicet Bio (ACET) - Defense World
Adicet Bio shares hold neutral rating amid positive study data By Investing.com - Investing.com South Africa
Adicet Bio shares hold neutral rating amid positive study data - Investing.com
Adicet Bio shares hold neutral rating amid positive study data By Investing.com - Investing.com Canada
Adicet Bio (NASDAQ:ACET) Earns Outperform Rating from Wedbush - MarketBeat
Adicet Bio (NASDAQ:ACET) Receives Neutral Rating from HC Wainwright - Defense World
Adicet Bio reports promising ADI-001 therapy data - Investing.com
HC Wainwright Reiterates "Neutral" Rating for Adicet Bio (NASDAQ:ACET) - MarketBeat
Adicet Bio reports promising ADI-001 therapy data By Investing.com - Investing.com Australia
Adicet Bio reports promising ADI-001 therapy data - Investing.com India
ADI-001 Clinical Biomarker Data Demonstrate Robust Tissue Trafficking and Complete B Cell Depletion in Secondary Lymphoid Tissue - BioSpace
ADI-001 Clinical Biomarker Data Demonstrate Robust Tissue Trafficking and Complete B Cell Depletion in Secondary Lymphoid Tissue - Business Wire
Short Interest in Adicet Bio, Inc. (NASDAQ:ACET) Declines By 10.3% - MarketBeat
Adicet Bio, Inc. (NASDAQ:ACET) Shares Bought by Acadian Asset Management LLC - MarketBeat
Adicet Bio, Inc. (NASDAQ:ACET) Shares Purchased by Acadian Asset Management LLC - Defense World
Adicet Bio, Inc. (NASDAQ:ACET) Expected to Earn FY2026 Earnings of ($1.11) Per Share - Defense World
Insider Selling: Kauffman Michael, Adicet Bio Inc [ACET] Director divested 5,900 shares - Knox Daily
Adicet Bio, Inc. (NASDAQ:ACET) Forecasted to Post FY2026 Earnings of ($1.11) Per Share - MarketBeat
ACET’s Stock Market Adventure: -19.05% YTD Growth Amidst Volatility - The InvestChronicle
Check Out Adicet Bio Inc (ACET)’s Trade Data Rather Than the Analysts’ Views - SETE News
Adicet Bio (NASDAQ:ACET) Given New $8.00 Price Target at Canaccord Genuity Group - Defense World
Adicet Bio stock target cut by Canaccord Genuity on adjusted expectations - Investing.com
Adicet Bio (NASDAQ:ACET) Lowered to Neutral at HC Wainwright - Defense World
Adicet Bio (NASDAQ:ACET) Price Target Lowered to $8.00 at Canaccord Genuity Group - MarketBeat
Adicet Bio stock slips on narrowed focus (NASDAQ:ACET) - Seeking Alpha
Adicet Bio stock target cut by Canaccord Genuity on adjusted expectations - Investing.com Canada
Adicet Bio stock target cut by Canaccord Genuity on adjusted expectations - Investing.com India
Adicet Bio (NASDAQ:ACET) Downgraded to "Neutral" at HC Wainwright - MarketBeat
Adicet Bio stock target cut by Canaccord Genuity on adjusted expectations - Investing.com UK
Adicet Bio (NASDAQ:ACET) Given Outperform Rating at Wedbush - Defense World
Adicet Bio shifts focus to autoimmune diseases, ends lymphoma study By Investing.com - Investing.com Australia
Adicet Bio shares target cut to $4, maintains buy rating - Investing.com
Adicet Bio shares target cut to $4, maintains buy rating By Investing.com - Investing.com Australia
Adicet Bio (NASDAQ:ACET) Downgraded by StockNews.com to Sell - Defense World
StockNews.com Downgrades Adicet Bio (NASDAQ:ACET) to Sell - MarketBeat
Adicet Bio shares target cut to $4, maintains buy rating By Investing.com - Investing.com Canada
Adicet Bio's (ACET) Outperform Rating Reaffirmed at Wedbush - MarketBeat
Adicet Bio shifts focus to autoimmune diseases, ends lymphoma study - Investing.com India
Adicet Bio shifts focus to autoimmune diseases, ends lymphoma study By Investing.com - Investing.com Canada
Adicet Bio shifts focus to autoimmune diseases, ends lymphoma study By Investing.com - Investing.com UK
Adicet Bio Inc (ACET)’s stock price in review: A technical analysis - US Post News
Adicet Bio Inc Stock (ACET) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):